NAGE Share Price Performance
US$5.06
-2.64 (-34.29%)
62.8% undervalued intrinsic discount
US$13.60
Fair Value
Price US$5.06
AnalystConsensusTarget US$13.60
AnalystLowTarget US$12.00
AnalystHighTarget US$23.00
Fair ValueUS$13.60
Share Pricen/a
Niagen Bioscience, Inc. Stock Price
- 3 Narratives written by author
- 1 Comments on narratives written by author
- 55 Fair Values set on narratives written by author
NAGE Community Narratives
AN
Fair Value US$13.6 62.8% undervalued intrinsic discount
Niagen IV Launch And E-commerce Growth Will Strengthen Future Prospects
2users have liked this narrative
1users have commented on this narrative
24users have followed this narrative
AN
Fair Value US$12 57.8% undervalued intrinsic discount
NAD Market Competition And Regulatory Risks Will Challenge Margins Yet Support Long-Term Healthy Aging Demand
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
Fair Value US$23 78.0% undervalued intrinsic discount
Expanding NAD Category And Clinical Pipeline Will Drive Powerful Long-Term Upside
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Niagen IV Launch And E-commerce Growth Will Strengthen Future Prospects
Key Takeaways Expansion into pharmaceutical-grade Niagen and increased e-commerce performance could drive revenue growth through direct-to-consumer channels and enhanced demand. Increased R&D investments and legal settlements might strengthen the balance sheet and lead to potential high-margin pharmaceutical developments.Read more
384
users have viewed this narrative2users have liked this narrative
1users have commented on this narrative
24users have followed this narrative
AN
US$13.6
62.8% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
18.14% p.a.
Profit Margin
19.07%
Future PE
34.52x
Price in 2029
US$16.66
Expanding NAD Category And Clinical Pipeline Will Drive Powerful Long-Term Upside
Catalysts About Niagen Bioscience Niagen Bioscience develops and commercializes scientifically validated NAD boosting ingredients and products that promote healthy aging across consumer, clinical and potential pharmaceutical applications. What are the underlying business or industry changes driving this perspective?Read more
44
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$23
78.0% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
21.08% p.a.
Profit Margin
22.75%
Future PE
49.65x
Price in 2029
US$29.9
NAD Market Competition And Regulatory Risks Will Challenge Margins Yet Support Long-Term Healthy Aging Demand
Catalysts About Niagen Bioscience Niagen Bioscience develops and commercializes clinically validated NAD boosting ingredients and products that target healthy aging and metabolic health. What are the underlying business or industry changes driving this perspective?Read more
55
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
US$12
57.8% undervalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
19.5% p.a.
Profit Margin
19.61%
Future PE
31.27x
Price in 2028
US$15
Trending Discussion
Recently Updated Narratives
AN
NAGE: Core Demand And Injectables Outlook Will Support Future Upside
Fair Value: US$13.6 62.8% undervalued intrinsic discount
24 followersusers have followed this narrative
1 commentusers have commented on this narrative
0 likesusers have liked this narrative
AN
Expanding NAD Category And Clinical Pipeline Will Drive Powerful Long-Term Upside
Fair Value: US$23 78.0% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
NAD Market Competition And Regulatory Risks Will Challenge Margins Yet Support Long-Term Healthy Aging Demand
Fair Value: US$12 57.8% undervalued intrinsic discount
3 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Niagen Bioscience, Inc. Key Details
About NAGE
- Founded
- 1999
- Employees
- 104
- CEO
- WebsiteView website
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceutical-grade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products. In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and authorized healthcare practitioners resellers. The company was formerly known as ChromaDex Corporation and changed its name to Niagen Bioscience, Inc. in March 2025. Niagen Bioscience, Inc. was founded in 1999 and is headquartered in Los Angeles, California.
